Kai Yi Mok

Kai Yi Mok

Auto-generated profile, based on publicly available information

Kai Yi Mok

Faculty of Medicine, Department of Infectious Disease, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CTCedric C. S. Tan
Cedric C. S. Tan
JTJahcub Trew
Jahcub Trew
TPThomas Peacock
Thomas Peacock
KMKai Yi Mok
Kai Yi Mok
CHCharlie Hart
Charlie Hart
VSVincent Savolainen
Vincent Savolainen
There has been limited characterisation of bat-borne coronaviruses in Europe. Here, we screened for coronaviruses in 48 faecal samples from 16 of the 17 bat species breeding in the UK, collected through a bat rehabilitation and conservationist network. We recovered nine complete genomes, including two novel coronavirus species, across six bat species: four alphacoronaviruses, a MERS-related betacoronavirus, and four closely related sarbecoviruses. We demonstrate that at least one of these sarbecoviruses can bind and use the human ACE2 receptor for infecting human cells, albeit suboptimally. Additionally, the spike proteins of these sarbecoviruses possess an R-A-K-Q motif, which lies only one nucleotide mutation away from a furin cleavage site (FCS) that enhances infectivity in other coronaviruses, including SARS-CoV-2. However, mutating this motif to an FCS does not enable spike cleavage. Overall, while UK sarbecoviruses would require further molecular adaptations to infect humans, their zoonotic risk warrants closer surveillance.

11 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSinead McCabe
Sinead McCabe
RZRuiqi Zhu
Ruiqi Zhu
RSRaag Yagnik Setia
Raag Yagnik Setia
JBJonathan C. Brown
Jonathan C. Brown
ZPZiyi Pan
Ziyi Pan
ANAdrian Najer
Adrian Najer
A broad-spectrum antiviral is required to enable rapid intervention against current, newly emerging and mutating viruses. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus (IAV), Sindbis virus (SINV) and chikungunya virus (CHIKV) all engage negatively charged moieties on host cells, such as heparan sulfate (HS) and sialic acid, to facilitate attachment for entry and infection. We designed HS-mimetic nanoparticles in the form of polymer vesicles (polymersomes) by blending membrane-forming and sulfonated copolymers. These biocompatible polymersomes successfully inhibited host cell infection of HS-dependent SARS-CoV-2 and HS-independent IAV in vitro with sub-nanomolar potency. Multivalent interaction of several virus ligands with a single polymersome as quantified by fluorescence correlation spectroscopy likely contributes to their potency. The sulfonated polymersomes also functioned in vivo as demonstrated by a reduction in the spread of SINV, an alphavirus model for CHIKV, in zebrafish embryos, which led to a significantly increased survival. Hence, our polymersomes could form the basis for an urgently required multifunctional broad-spectrum antiviral nanomedicine.